Rani Therapeutics Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.06
- Today's High:
- $3.5699
- Open Price:
- $3.4
- 52W Low:
- $3.06
- 52W High:
- $10.8
- Prev. Close:
- $3.45
- Volume:
- 53477
Company Statistics
- Market Cap.:
- $193.90 million
- Book Value:
- 0.944
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $2.72 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.67%
- Return on Equity TTM:
- -94.05%
Company Profile
Rani Therapeutics Holdings Inc had its IPO on 2021-07-30 under the ticker symbol RANI.
The company operates in the Healthcare sector and Biotechnology industry. Rani Therapeutics Holdings Inc has a staff strength of 163 employees.
Stock update
Shares of Rani Therapeutics Holdings Inc opened at $3.4 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.06 - $3.57, and closed at $3.08.
This is a -10.72% slip from the previous day's closing price.
A total volume of 53,477 shares were traded at the close of the day’s session.
In the last one week, shares of Rani Therapeutics Holdings Inc have slipped by -18.95%.
Rani Therapeutics Holdings Inc's Key Ratios
Rani Therapeutics Holdings Inc has a market cap of $193.90 million, indicating a price to book ratio of 4.6693 and a price to sales ratio of 313.1706.
In the last 12-months Rani Therapeutics Holdings Inc’s revenue was $0 with a gross profit of $2.72 million and an EBITDA of $-67942000. The EBITDA ratio measures Rani Therapeutics Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Rani Therapeutics Holdings Inc’s operating margin was 0% while its return on assets stood at -45.67% with a return of equity of -94.05%.
In Q2, Rani Therapeutics Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Rani Therapeutics Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rani Therapeutics Holdings Inc’s profitability.
Rani Therapeutics Holdings Inc stock is trading at a EV to sales ratio of 84.2765 and a EV to EBITDA ratio of -1.9562. Its price to sales ratio in the trailing 12-months stood at 313.1706.
Rani Therapeutics Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $83.51 million
- Total Liabilities
- $5.74 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $335000
- Dividend Payout Ratio
- 0%
Rani Therapeutics Holdings Inc ended 2024 with $83.51 million in total assets and $0 in total liabilities. Its intangible assets were valued at $83.51 million while shareholder equity stood at $24.09 million.
Rani Therapeutics Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $5.74 million in other current liabilities, 5000.00 in common stock, $-56594000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.55 million and cash and short-term investments were $74.61 million. The company’s total short-term debt was $856,000 while long-term debt stood at $29.27 million.
Rani Therapeutics Holdings Inc’s total current assets stands at $76.37 million while long-term investments were $0 and short-term investments were $67.05 million. Its net receivables were $0 compared to accounts payable of $1.04 million and inventory worth $0.
In 2024, Rani Therapeutics Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $335000.
Comparatively, Rani Therapeutics Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.08
- 52-Week High
- $10.8
- 52-Week Low
- $3.06
- Analyst Target Price
- $22.25
Rani Therapeutics Holdings Inc stock is currently trading at $3.08 per share. It touched a 52-week high of $10.8 and a 52-week low of $10.8. Analysts tracking the stock have a 12-month average target price of $22.25.
Its 50-day moving average was $4.09 and 200-day moving average was $5.28 The short ratio stood at 30.14 indicating a short percent outstanding of 0%.
Around 5116.5% of the company’s stock are held by insiders while 1184.2% are held by institutions.
Frequently Asked Questions About Rani Therapeutics Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.